Positron-Emission Tomography
Top in cardiology: Obesity drug for those with heart failure; new cardiac PET agent
A novel controlled metabolic accelerator was associated with weight loss in patients with obesity-related heart failure with preserved ejection fraction, according to phase 2a study results.
FDA approves novel PET radiotracer for evaluation of suspected MI, ischemia
The FDA approved 18F flurpiridaz, a new cardiac PET perfusion radiotracer, for adult patients with known or suspected coronary artery disease being evaluated for myocardial ischemia and infarction.
Lantheus acquires Meilleur, including global rights to PET imaging agent for Alzheimer’s
Lantheus Holdings Inc. has announced the acquisition of Meilleur Technologies Inc., which includes the transfer of its rights to an amyloid-beta positron emission tomography imaging agent.
FDA grants fast track designation to PET tau imaging tracer
The FDA has granted fast track designation to a radioactive fluorinated positron emission tomography tracer for imaging tau protein in those with suspected progressive supranuclear palsy, according to the manufacturer.
Ability to detect CAD confirmed for PET with novel radiotracer
Confirming a previous report, PET with a novel radiotracer had good sensitivity and specificity for CAD detection and outperformed single-photon emission CT myocardial perfusion imaging.
Early amyloid PET provides high diagnostic confidence for adults with cognitive impairment
Access to early amyloid position emission tomography allowed those with memory issues to receive a diagnosis with very high confidence at 3 months compared with those who did not undergo PET, according to research in JAMA Neurology.
PET with novel radiotracer able to detect CAD, superior to SPECT
PET with a novel radiotracer met its primary endpoint for sensitivity and specificity of CAD detection, researchers reported at the Annual Scientific Session and Exhibition of the American Society of Nuclear Cardiology.
Tau PET imaging represents 'promising tool' for predicting changes in cognitive status
FDA approves Pylarify, PET imaging agent for prostate cancer
The FDA approved piflufolastat F 18 injection, a radioactive diagnostic agent designed to identify suspected metastasis or recurrence of prostate cancer, according to the agent’s manufacturer.
FDA approves PET imaging drug for prostate cancer
The FDA today approved Gallium 68 PSMA-11 as the first drug for PET imaging of prostate-specific membrane antigen-positive lesions in men with prostate cancer, according a press release from the agency.